CAPPED BONUS CERTIFICATE - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 20:35:23 19/06/2024 BST | ||
| 97.55 EUR | +0.31% |
|
| Current month | +2.35% | ||
| 1 month | +4.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 97.53 | +0.29% |
| 18/06/24 | 97.25 | +0.02% |
| 17/06/24 | 97.23 | -0.11% |
| 14/06/24 | 97.34 | +0.13% |
| 13/06/24 | 97.21 | -0.25% |
Real-time Boerse Frankfurt Warrants
Last update June 19, 2024 at 08:35 pm
More quotesStatic data
| Product type | Certificados de Bonus y Protección Parcial |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW93GD |
| ISIN | DE000SW93GD7 |
| Date issued | 08/05/2024 |
| Strike | 1,000 kr |
| Maturity | 20/09/2024 (93 Days) |
| Parity | 10 : 1 |
| Emission price | 90.7 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 98 € |
|---|---|
| Lowest since issue | 90.79 € |
| Spread | 0.58 € |
| Spread % | 0.59% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984.2
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.07%
- Stock Market
- Certificates
- Certificat
